Breast TumorMACS Medium is an optimized serum-free cell culture medium for the cultivation and expansion of tumor cells from primary and xenotransplanted breast tumors. It enables the establishment of stable cell lines from freshly dissociated tumor tissue.
The medium supports the transition of tumor cells into physiologically relevant 3D culture formats, including tumor organoids and tumoroids.
Related products for Breast TumorMACS™ Medium, human
Breast TumorMACS Medium is an optimized serum-free cell culture medium for the cultivation and expansion of tumor cells from primary and xenotransplanted breast tumors. It enables the establishment of stable cell lines from freshly dissociated tumor tissue.
The medium supports the transition of tumor cells into physiologically relevant 3D culture formats, including tumor organoids and tumoroids.
The Breast TumorMACS Medium is an optimized and standardized medium for the reliable expansion of tumor cells from primary or xenotransplanted human breast tumor samples. Tumor cells from freshly dissociated tissue can be cultured over multiple passages, allowing for in vitro assays, such as drug screenings on primary cell cultures or characterization studies including gene expression or protein profiling.
In addition, the Breast TumorMACS Medium supports the establishment of new cell lines and thereby obtaining sufficient cell numbers for further experiments, such as in vivo transplantation studies in animals.
Breast TumorMACS Medium efficiently expands cultures of primary breast tumor cells in vitro while maintaining the cell populations' heterogeneity and tumorigenic potential. The medium is manufactured under strictly controlled conditions using ingredients of the highest quality.
Breast TumorMACS Medium offers consistent lot-to-lot performance and optimal conditions for the cultivation of primary breast tumor cells.
- Schwerd-Kleine, P. et al. (2025) Biopsy-derived organoids in personalised early breast cancer care: Challenges of tumour purity and normal cell overgrowth cap their practical utility. Int. J. Cancer 156 (11): 2200-2209
- Würth, R. et al. (2025) Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1-HER3 signaling Nat Cancer 6 (1): 67-85
You have previously chosen International as your location.
What do you want to do?